Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Vyant Bio, Inc. VYNT
$0.27
-$0.05 (-18.18%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
2032618.00000000
-
week52high
4.95
-
week52low
0.27
-
Revenue
666000
-
P/E TTM
0
-
Beta
0.52791800
-
EPS
-2.67000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 17 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 08 мар 2022 г. |
| HC Wainwright & Co. | Buy | 06 окт 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Horobin Joanna | A | 23123 | 7526 | 17 янв 2023 г. |
| Harris Geoffrey E. | A | 19761 | 5712 | 17 янв 2023 г. |
| FLETCHER R JOHN | A | 23895 | 4368 | 17 янв 2023 г. |
| Hansen Paul R. | A | 152995 | 4032 | 17 янв 2023 г. |
| Harris Geoffrey E. | D | 14019 | 666 | 18 ноя 2022 г. |
| Harris Geoffrey E. | D | 14685 | 99 | 18 ноя 2022 г. |
| FLETCHER R JOHN | A | 97649 | 8290 | 17 окт 2022 г. |
| Hansen Paul R. | A | 744826 | 7653 | 17 окт 2022 г. |
| Harris Geoffrey E. | A | 73920 | 10841 | 17 окт 2022 г. |
| Horobin Joanna | A | 77994 | 14285 | 17 окт 2022 г. |
Новостная лента
Vyant Bio to pursue listing on OTC Pink Open Market
Proactive Investors
12 мая 2023 г. в 09:21
Vyant Bio (NASDAQ:VYNT) said its last day of trading on the Nasdaq Capital Market will be May 12, 2023. following its filing to voluntarily delist from the exchange.
Why Is Vyant Bio (VYNT) Stock Down 35% Today?
InvestorPlace
25 апр 2023 г. в 08:53
Vyant Bio (NASDAQ: VYNT ) stock is taking a beating on Tuesday after the biotechnology company announced plans to delist its shares. According to a press release, the company's Board of Directors determined that a voluntary delisting of shares was in order.
Vyant Bio commences cash conservation plan including ‘reduction in force' as it continues to explore strategic alternatives
Proactive Investors
03 февр 2023 г. в 07:02
Vyant Bio (NASDAQ:VYNT) has told investors that the company's president and CEO John Roberts and chief scientific officer Dr Robert Fremeau have agreed in principle to step down from their respective positions, effective today, February 3, to preserve cash for the execution of an orderly wind-down process. Roberts will remain a member of the board of directors, while chief financial officer Andrew LaFrence will assume the position of president CEO to lead the company through the period of transition, New Jersey-based Vyant said in a statement.
Vyant Bio appoints LifeSci Capital to review strategy focused on enhancing shareholder value
Proactive Investors
04 янв 2023 г. в 16:43
Vyant Bio (NASDAQ:VYNT) Inc has engaged LifeSci Capital as its financial advisor to assist in exploring a range of strategic alternatives focused on enhancing shareholder value. The biotechnology company also said it is participating in BIO's One-on-One Partnering event in San Francisco taking place at the same time as the annual JP Morgan Healthcare Conference.
Vyant Bio, Inc. (VYNT) Q3 2022 Earnings Call Transcript
Seeking Alpha
17 ноя 2022 г. в 17:26
Vyant Bio, Inc. (NASDAQ:VYNT ) Q3 2022 Earnings Conference Call November 16, 2022 4:30 PM ET Company Participants Jay Roberts - Chief Executive Officer Andy LaFrence - Chief Financial Officer Dr. Robert Fremeau - Chief Scientific Officer Conference Call Participants Ed White - H.C. Wainwright Operator Thank you for standing by.